Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1617 - 1624 of 12143 results
In with the Old, Out with the New: DOJ and FTC Issue Much-Anticipated Draft Merger Guidelines
July 26, 2023| Blog| Viewpoint
New DHS I-9 Regulation Provides Needed Flexibility to Certain Qualified Employers
July 26, 2023| Alert| Viewpoint
First Nonprescription Birth Control Pill Approved for Marketing by FDA: A Milestone for Reproductive Health
July 25, 2023| Blog| Viewpoint
Why Pharma Companies Should File Patents Later In The R&D Process
July 25, 2023| Blog| Viewpoint
California’s Highest Court Revisits Statutory PAGA Standing: What the Ruling Means for California Employers
July 25, 2023| Blog| Viewpoint
Why Is ‘Fiduciary’ Losing Its Luster?
July 25, 2023| News
Energy & Sustainability Connections Newsletter — July 2023
July 25, 2023| Article| Viewpoint
Energy & Sustainability Client Feature — July 2023
July 25, 2023| Article| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|